Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen <i>Mycobacterium tuberculosis</i>, which is difficult to rapidly diagnose and treat. There is an urgent ne...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonia Molloy, James Harrison, John S. McGrath, Zachary Owen, Clive Smith, Xin Liu, Xin Li, Jonathan A. G. Cox
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	tuberculosis <i>Mycobacterium</i> diagnostics drug discovery antibiotics antimicrobial resistance Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/18e9a61d9f4b42b7976d2b9eb9728489
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:18e9a61d9f4b42b7976d2b9eb9728489
record_format	dspace
spelling	oai:doaj.org-article:18e9a61d9f4b42b7976d2b9eb97284892021-11-25T18:25:11ZMicrofluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery10.3390/microorganisms91123302076-2607https://doaj.org/article/18e9a61d9f4b42b7976d2b9eb97284892021-11-01T00:00:00Zhttps://www.mdpi.com/2076-2607/9/11/2330https://doaj.org/toc/2076-2607Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen <i>Mycobacterium tuberculosis</i>, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in <i>M. tuberculosis</i> diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.Antonia MolloyJames HarrisonJohn S. McGrathZachary OwenClive SmithXin LiuXin LiJonathan A. G. CoxMDPI AGarticletuberculosis<i>Mycobacterium</i>diagnosticsdrug discoveryantibioticsantimicrobial resistanceBiology (General)QH301-705.5ENMicroorganisms, Vol 9, Iss 2330, p 2330 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tuberculosis <i>Mycobacterium</i> diagnostics drug discovery antibiotics antimicrobial resistance Biology (General) QH301-705.5
spellingShingle	tuberculosis <i>Mycobacterium</i> diagnostics drug discovery antibiotics antimicrobial resistance Biology (General) QH301-705.5 Antonia Molloy James Harrison John S. McGrath Zachary Owen Clive Smith Xin Liu Xin Li Jonathan A. G. Cox Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
description	Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen <i>Mycobacterium tuberculosis</i>, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in <i>M. tuberculosis</i> diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.
format	article
author	Antonia Molloy James Harrison John S. McGrath Zachary Owen Clive Smith Xin Liu Xin Li Jonathan A. G. Cox
author_facet	Antonia Molloy James Harrison John S. McGrath Zachary Owen Clive Smith Xin Liu Xin Li Jonathan A. G. Cox
author_sort	Antonia Molloy
title	Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
title_short	Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
title_full	Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
title_fullStr	Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
title_full_unstemmed	Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
title_sort	microfluidics as a novel technique for tuberculosis: from diagnostics to drug discovery
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/18e9a61d9f4b42b7976d2b9eb9728489
work_keys_str_mv	AT antoniamolloy microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery AT jamesharrison microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery AT johnsmcgrath microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery AT zacharyowen microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery AT clivesmith microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery AT xinliu microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery AT xinli microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery AT jonathanagcox microfluidicsasanoveltechniquefortuberculosisfromdiagnosticstodrugdiscovery
_version_	1718411182043299840

Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Ejemplares similares